Botanical Adulteration in EU Herbal Supplements: Why DNA Barcoding Is Overturning Traditional Identity Testing

In 2013, a research team published a DNA barcoding analysis of 44 commercial herbal products purchased from 12 companies across North America. Their findings were stark: 30 of the 44 products — 68% — contained plant species not declared anywhere on the label. In some cases, the named botanical was absent entirely, replaced by a cheaper substitute. In others, the correct species was present but diluted with undisclosed fillers. Only 2 of the 12 companies had every single product pass authentication testing (Newmaster et al., BMC Medicine, 2013).

That study used North American retail products. But the raw material supply chains feeding European herbal supplement manufacturers are largely the same: the same Indian and Chinese origin facilities, the same international brokers, the same limited quality gates between cultivation site and European formulation floor. European brands are not insulated from this problem. They’re simply operating within a regulatory environment that hasn’t yet made DNA-based botanical identity testing explicitly mandatory — which creates a dangerous assumption that traditional methods are sufficient.

They’re often not. And the trajectory of the European Pharmacopoeia and EMA’s Committee on Herbal Medicinal Products suggests regulators are well aware of this.

Why Microscopy and TLC Have Structural Limits

Traditional botanical identity methods — organoleptic assessment, optical microscopy, and thin-layer chromatography (TLC) — were developed for raw plant material arriving from short, transparent supply chains. They work reasonably well when you’re examining whole or coarsely cut dried chamomile flowers from a regional grower and can assess cellular morphology directly.

They struggle in three specific scenarios that now define most European supplement sourcing.

Powdered or extracted materials. Once a botanical is ground to powder or further processed into a dry extract, the cellular architecture that microscopy relies on is largely destroyed. A skilled microscopist can still identify characteristic starch grains, calcium oxalate crystal forms, or trichome fragments — but the resolution and confidence level drop substantially. TLC can confirm the presence of key marker compounds (curcuminoids in turmeric, rosmarinic acid in rosemary), but it identifies a chemical class, not a species. A botanical that contains the right compounds at sufficient concentration will pass TLC even if minor adulteration is present.

Inter-species substitution within a genus. Echinacea is the clearest European example. The three commercially relevant species — E. purpurea, E. angustifolia, and E. pallida — share overlapping phytochemical profiles but have meaningfully different pharmacological activities and distinct regulatory status. EMA’s HMPC Community Herbal Monographs treat them as separate herbal substances, each with its own identity and quality requirements. TLC won’t reliably distinguish them. Microscopy in powdered form is interpretively difficult. A supplier substituting the cheaper E. pallida for specification E. purpurea can clear a traditional identity test without difficulty.

Multi-ingredient botanical blends. If you’re testing a product containing seven or eight botanicals, TLC chromatograms become nearly unreadable — marker bands from legitimate ingredients overlap and mask the signals you’re looking for. The analytical noise scales with complexity in a way that systematically reduces detection sensitivity.

The Association of the European Self-Care Industry (AESGP) has flagged botanical identity verification in complex matrices as one of the persistent quality gaps in the European herbal supplement sector. The European Directorate for the Quality of Medicines & HealthCare (EDQM), which maintains the European Pharmacopoeia, has been integrating DNA-based methods into Ph.Eur. general chapters precisely because classical methods have reached their resolution ceiling.

How DNA Barcoding Works — and Where Its Own Limits Lie

DNA barcoding sequences one or more short, standardised genetic regions from a sample and compares the result against a curated reference database. For plant materials, the standard Consortium for the Barcode of Life (CBOL) marker regions are rbcL (ribulose-bisphosphate carboxylase large subunit) and matK (maturase K), both encoded in the chloroplast genome. A third region, ITS2 (internal transcribed spacer 2), offers strong discriminatory power for flowering plants and is referenced in European Pharmacopoeia chapters on DNA-based botanical characterisation.

Even in powdered matrices or moderately processed extracts, plant cells retain enough intact DNA for barcoding — provided the extraction process hasn’t been so harsh as to severely degrade the genetic material (high-temperature, high-pressure extraction can reduce DNA yield, though a competent laboratory will optimise accordingly). The method can confirm Echinacea purpurea versus E. pallida with high confidence. It can distinguish Withania somnifera (ashwagandha) from W. coagulans, a known substitute that shares morphological similarity but lacks the withanolide profile that makes ashwagandha commercially valuable.

For complex multi-ingredient formulas, a more sophisticated approach — next-generation sequencing-based metabarcoding — sequences all DNA present in a sample simultaneously, generating a species inventory of everything actually in the product. Some laboratories in North America now run this routinely on finished botanical blends as a final lot-release check.

But there is a structural limitation every quality professional needs to internalise: DNA barcoding identifies the biological source of the material. It says nothing about chemical composition or non-botanical adulterants.

Turmeric (Curcuma longa) makes this point clearly. DNA barcoding confirms you’re working with Curcuma longa, not a substitute species. It does not detect synthetic curcumin added to inflate apparent curcuminoid content. It does not detect metanil yellow, a non-permitted azo dye historically used to enhance colour. It does not reveal whether the 95% curcuminoid claim on the specification sheet is real — that requires HPLC quantification. Lead chromate has been documented as a turmeric adulterant in some supply chains; detecting it requires ICP-MS heavy metal analysis, not barcoding.

The same logic applies to ashwagandha: DNA confirms the species, but withanolide content quantification still requires HPLC against a validated reference standard.

A rigorous botanical identity programme uses DNA as the species-confirmation layer and combines it with appropriate chemical characterisation. Neither method alone is sufficient for high-risk materials.

The EU Regulatory Framework: What HMPC Monographs and Ph.Eur. Actually Require

European brands often misread where the regulatory floor sits for botanical identity, particularly when the same ingredient appears in products across different regulatory categories.

Under Directive 2004/24/EC (the Traditional Herbal Medicinal Products directive, amending 2001/83/EC), botanical herbal substances used in THMPs registered in an EU member state must meet the identity criteria set out in the relevant EMA HMPC Community Herbal Monograph and/or the relevant European Pharmacopoeia monograph. These monographs specify Latin binomial, plant part, acceptable preparation, and minimum marker compound content. Identity testing requirements are part of the quality dossier — not optional.

For food supplements governed by EU Regulation 2002/46/EC, the regulatory framework is less prescriptive at the product level. Identity requirements sit within the broader GMP obligations that apply to supplement manufacturers operating in the EU. But if a product triggers a safety query — through RASFF (Rapid Alert System for Food and Feed), a national competent authority like France’s DGCCRF or Germany’s BfR, or an EFSA assessment — the first documentation request will cover botanical identity. A TLC chromatogram submitted without voucher specimen reference data or an accompanying expert botanical opinion is a weak defence.

The European Pharmacopoeia’s progressive inclusion of DNA-based identification methods for specific botanicals — including Echinacea purpurea herb, Ginkgo biloba leaf, and Valeriana officinalis root — signals the direction of travel. Regulatory assessors increasingly understand what a DNA identity report should contain and how it compares with a classical microscopy report. That context matters when a dossier is under scrutiny.

There’s a further consideration for any brand whose botanical ingredients appear on EFSA’s rolling assessment lists — either as potential Novel Foods or as substances under review by the EFSA Plants Expert Group (which evaluates botanicals with potential safety concerns). Having robust, method-appropriate identity documentation doesn’t just demonstrate quality. It demonstrates you’re working with the correctly identified, properly specified substance, which is foundational to any safety argument.

Building a Testing Protocol That Actually Holds Up

After years of working with European brands trying to align their botanical sourcing practices with modern regulatory expectations, a few structural choices consistently determine whether a quality programme holds up under scrutiny.

Test at the raw material stage, before anything enters your process. By the time a botanical has been blended, granulated, or encapsulated, your testing options narrow considerably and the cost of a rejection is far higher. Identity testing on incoming raw materials, against a clearly documented specification, is both more reliable analytically and more defensible from a GMP perspective under ISO 22716 and EU pharmaceutical GMP principles.

Match the method to the matrix and the risk profile. Whole dried leaf from a long-qualified supplier with a clean audit history? TLC plus organoleptic assessment may be proportionate. Powdered root extract from a new supplier making high-potency curcuminoid claims? DNA barcoding plus HPLC quantification plus ICP-MS heavy metals, at minimum. Risk-based method selection, documented and justified, is what competent authorities are looking for.

Require more than a Certificate of Analysis from your suppliers. A CoA confirms that someone ran tests. It doesn’t confirm what species is actually in the bag. For botanical raw materials, require a Certificate of Botanical Identity (COBI) supported by a voucher specimen reference, macroscopic and microscopic examination records, or — for higher-risk materials — a third-party DNA report from an accredited laboratory. The difference between a supplier who can produce this and one who cannot tells you something meaningful about their quality infrastructure.

Build a documented supplier qualification programme. Under EU GMP expectations and ISO 22716, supplier qualification is a documented, risk-based process — not a one-time form. An audit trail demonstrating that you evaluated your botanical supplier’s identity controls, not just their pricing, is substantive protection if a question ever reaches the competent authority level.

Our team connects European supplement and cosmetic brands with ISO 17025-accredited laboratory capabilities in the US and Canada where DNA barcoding and NGS-based metabarcoding are substantially more established than in Europe, and where data packages can be formatted specifically for EU regulatory submissions and HMPC dossier requirements.

Why Access to DNA Testing Is a Competitive Gap in Europe Right Now

DNA barcoding for botanical identity is genuinely less developed in the European laboratory landscape than in North America. Most EU-based accredited laboratories offer classical methods. A smaller number offer PCR-based identification for individual species. Laboratories routinely running NGS metabarcoding on complex botanical matrices — with validated reference libraries and results formatted for regulatory use — remain uncommon.

That gap creates a real quality asymmetry. European brands are competing in a global supplement market where some North American brands already validate every botanical raw material lot with DNA barcoding as standard practice. If adulteration does occur in your supply chain and a market surveillance body identifies it, the question of whether you used best-available methods will matter. “We tested by the methods available to us locally” becomes harder to sustain as an argument each year that better methods become more accessible.

The regulatory direction is clear. Brands that build DNA-inclusive identity testing into their supply chains now — through partner laboratory arrangements if not internal capability — won’t be caught off-guard when it becomes an explicit requirement rather than a best-practice recommendation.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry. Contact us

Related from our network

• ISO 17025-Accredited Botanical Identity & Adulteration Testing — Qalitex Laboratories offers DNA barcoding, NGS metabarcoding, and HPLC marker compound quantification for botanical raw materials, with data packages formatted for EU and US regulatory submissions.
• Herbal Supplement Testing for Health Canada NHPD Compliance — Androxa supports Canadian NHP licence applications with full botanical identity documentation, including DNA-based species confirmation for complex herbal matrices.